KIT and gastrointestinal stromal tumor: Another inhibitor, avapritinib (BLU-285), was developed as a selective inhibitor for mutant KIT and recently received FDA approval for the treatment of advanced GIST harboring a PDGFRA exon 18 mutation [11, 35].